OncoSec Medical Inc.

Company Snapshot: OncoSec Medical Inc.

Last Change Volume High Low

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.

Featured Documents

Client News

  1. Sep 4 2018 OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
  2. Aug 31 2018 OncoSec to Present at H.C. Wainwright 20th Annual Global Investment Conference
  3. Aug 28 2018 OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
  4. Aug 6 2018 OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.